Zemcelpro®, UM171 Zemcelpro® receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells Veröffentlicht: 27.08.2025 um 13:01 Uhr, prnewswire.co.uk ExCellThera Quebec Europe View original content:https://www.prnewswire.co.uk/news-releases/zemcelpro-um171-cell-therapy-receives-ec-authorization-as-the-first-and-only-cell-therapy-for-blood-cancer-patients-without-access-to-suitable-donor-cells-302539246.html en | boerse | 68150467 |
